PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 85 filers reported holding PHATHOM PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,377,021 | -27.6% | 422,085 | 0.0% | 0.98% | -12.8% |
| Q2 2023 | $6,044,257 | +100.6% | 422,085 | 0.0% | 1.12% | +99.6% |
| Q1 2023 | $3,013,687 | -36.4% | 422,085 | 0.0% | 0.56% | -9.4% |
| Q4 2022 | $4,735,794 | +1.3% | 422,085 | 0.0% | 0.62% | -7.1% |
| Q3 2022 | $4,677,000 | +31.3% | 422,085 | 0.0% | 0.66% | +74.5% |
| Q2 2022 | $3,562,000 | -38.0% | 422,085 | 0.0% | 0.38% | -11.0% |
| Q1 2022 | $5,745,000 | -30.8% | 422,085 | 0.0% | 0.43% | -9.5% |
| Q4 2021 | $8,302,000 | -38.7% | 422,085 | 0.0% | 0.47% | -46.1% |
| Q3 2021 | $13,549,000 | – | 422,085 | – | 0.88% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 2,484,274 | $27,873,554 | 11.71% |
| Frazier Life Sciences Management, L.P. | 8,407,152 | $94,328,245 | 5.86% |
| Abingworth LLP | 1,435,106 | $16,101,889 | 5.25% |
| Opaleye Management Inc. | 417,500 | $4,684,350 | 1.63% |
| 683 Capital Management, LLC | 1,350,000 | $15,147,000 | 1.28% |
| Newtyn Management, LLC | 484,074 | $5,431,310 | 1.12% |
| Penn Mutual Asset Management | 62,802 | $704,638 | 0.79% |
| StepStone Group LP | 422,085 | $4,735,794 | 0.62% |
| MPM BioImpact LLC | 195,942 | $2,198,469 | 0.57% |
| Avidity Partners Management LP | 1,900,000 | $21,318,000 | 0.46% |